We’re a hybrid AI + biotech start-up, developing novel deep learning and molecular simulation techniques to predict molecular properties and using them to accelerate the development of new medicines. We raised a $52M Series A from Andreessen Horowit…

We’re a hybrid AI + biotech start-up, developing novel deep learning and molecular simulation techniques to predict molecular properties and using them to accelerate the development of new medicines. We raised a $52M Series A from Andreessen Horowit…

We’re a hybrid AI + biotech start-up, developing novel deep learning and molecular simulation techniques to predict molecular properties and using them to accelerate the development of new medicines. We raised a $52M Series A from Andreessen Horowit…

We’re a hybrid AI + biotech start-up, developing novel deep learning and molecular simulation techniques to predict molecular properties and using them to accelerate the development of new medicines. We raised a $52M Series A from Andreessen Horowit…

We’re a hybrid AI + biotech start-up, developing novel deep learning and molecular simulation techniques to predict molecular properties and using them to accelerate the development of new medicines. We raised $52M Series A from Andreessen Horowitz …

We’re a hybrid AI + biotech start-up, developing novel deep learning and molecular simulation techniques to predict molecular properties and using them to accelerate the development of new medicines. We raised $52M Series A from Andreessen Horowitz …